A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.

Published

Journal Article

PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib (1 mg/m(2) or 1.3 mg/m(2) IV bolus on days 1 and 8 of a 21-day cycle). RESULTS: Ten patients (median age 62 years), with a median of 3 prior regimens, were enrolled. Four (40%) patients achieved clinical benefit, with one patient achieving a durable partial response. No formal DLTs were encountered. CONCLUSION: AAV combination was feasible and demonstrated some benefits in this heavily pretreated population.

Full Text

Duke Authors

Cited Authors

  • Held, LA; Rizzieri, D; Long, GD; Gockerman, JP; Diehl, LF; de Castro, CM; Moore, JO; Horwitz, ME; Chao, NJ; Gasparetto, C

Published Date

  • March 2013

Published In

Volume / Issue

  • 31 / 3

Start / End Page

  • 172 - 176

PubMed ID

  • 23406188

Pubmed Central ID

  • 23406188

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

International Standard Serial Number (ISSN)

  • 0735-7907

Digital Object Identifier (DOI)

  • 10.3109/07357907.2012.756109

Language

  • eng